Search Results

There are 13140 results for: content related to: A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE -related hereditary hemochromatosis

  1. Deferasirox for managing iron overload in people with thalassaemia

    Intervention Review

    The Cochrane Library

    Claudia Bollig, Lisa K Schell, Gerta Rücker, Roman Allert, Edith Motschall, Charlotte M Niemeyer, Dirk Bassler and Joerg J Meerpohl

    Published Online : 15 AUG 2017, DOI: 10.1002/14651858.CD007476.pub3

  2. You have free access to this content
    Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia

    Intervention Review

    The Cochrane Library

    Sheila A Fisher, Susan J Brunskill, Carolyn Doree, Sarah Gooding, Onima Chowdhury and David J Roberts

    Published Online : 21 AUG 2013, DOI: 10.1002/14651858.CD004450.pub3

  3. You have full text access to this OnlineOpen article
    Long-term safety and efficacy of deferasirox (Exjade®) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease

    British Journal of Haematology

    Volume 154, Issue 3, August 2011, Pages: 387–397, Elliott Vichinsky, Françoise Bernaudin, Gian Luca Forni, Renee Gardner, Kathryn Hassell, Matthew M. Heeney, Baba Inusa, Abdullah Kutlar, Peter Lane, Liesl Mathias, John Porter, Cameron Tebbi, Felicia Wilson, Louis Griffel, Wei Deng, Vanessa Giannone and Thomas Coates

    Version of Record online : 19 MAY 2011, DOI: 10.1111/j.1365-2141.2011.08720.x

  4. You have free access to this content
    Deferasirox for managing transfusional iron overload in people with sickle cell disease

    Intervention Review

    The Cochrane Library

    Joerg J Meerpohl, Lisa K Schell, Gerta Rücker, Edith Motschall, Nigel Fleeman, Charlotte M Niemeyer and Dirk Bassler

    Published Online : 4 JUN 2014, DOI: 10.1002/14651858.CD007477.pub3

  5. Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease

    Journal of Clinical Pharmacy and Therapeutics

    Volume 37, Issue 2, April 2012, Pages: 173–181, L. B. Jordan, F. Vekeman, A. Sengupta, M. Corral, A. Guo and M. S. Duh

    Version of Record online : 18 MAY 2011, DOI: 10.1111/j.1365-2710.2011.01276.x

  6. Efficacy of Deferasirox for the treatment of iron overload in Chinese thalassaemia major patients: results from a prospective, open-label, multicentre clinical trial

    Transfusion Medicine

    Volume 23, Issue 6, December 2013, Pages: 389–396, Y.-R. Lai, R.-R. Liu, C.-F. Li, S.-L. Huang, Q. Li, D. Habr, N. Martin and Z.-X. Shen

    Version of Record online : 22 OCT 2013, DOI: 10.1111/tme.12077

  7. You have free access to this content
    Deferasirox for managing iron overload in people with myelodysplastic syndrome

    Intervention Review

    The Cochrane Library

    Joerg J Meerpohl, Lisa K Schell, Gerta Rücker, Nigel Fleeman, Edith Motschall, Charlotte M Niemeyer and Dirk Bassler

    Published Online : 28 OCT 2014, DOI: 10.1002/14651858.CD007461.pub3

  8. You have free access to this content
    Chelation treatment in sickle-cell-anaemia: much ado about nothing?

    British Journal of Haematology

    Volume 154, Issue 5, September 2011, Pages: 545–555, Gaetano Lucania, Angela Vitrano, Aldo Filosa and Aurelio Maggio

    Version of Record online : 28 JUN 2011, DOI: 10.1111/j.1365-2141.2011.08769.x

  9. Australian guidelines for the assessment of iron overload and iron chelation in transfusion-dependent thalassaemia major, sickle cell disease and other congenital anaemias

    Internal Medicine Journal

    Volume 41, Issue 7, July 2011, Pages: 516–524, P. J. Ho, L. Tay, R. Lindeman, L. Catley and D. K. Bowden

    Version of Record online : 18 JUL 2011, DOI: 10.1111/j.1445-5994.2011.02527.x

  10. Inconsistent hepatic antifibrotic effects with the iron chelator deferasirox

    Journal of Gastroenterology and Hepatology

    Volume 30, Issue 3, March 2015, Pages: 638–645, Amy Sobbe, Kim R Bridle, Lesley Jaskowski, C Erika de Guzman, Nishreen Santrampurwala, Andrew D Clouston, Catherine M Campbell, V Nathan Subramaniam and Darrell H G Crawford

    Version of Record online : 23 FEB 2015, DOI: 10.1111/jgh.12720

  11. You have full text access to this OnlineOpen article
    Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: Two-year results including pharmacokinetics and concomitant hydroxyurea

    American Journal of Hematology

    Volume 88, Issue 12, December 2013, Pages: 1068–1073, Elliott Vichinsky, Marcela Torres, Caterina P. Minniti, Stephane Barrette, Dany Habr, Yiyun Zhang, Beatrice Files and on behalf of the study CICL670A2201 investigators

    Version of Record online : 19 SEP 2013, DOI: 10.1002/ajh.23569

  12. You have free access to this content
    Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent β-thalassemia

    Pediatric Blood & Cancer

    Volume 56, Issue 3, March 2011, Pages: 420–424, Hsiu-Hao Chang, Meng-Yao Lu, Yu-Mei Liao, Pei-Chin Lin, Yung-Li Yang, Dong-Tsamn Lin, Shyh-Shin Chiou, Shiann-Tarng Jou, Kai-Hsin Lin and Tai-Tsung Chang

    Version of Record online : 11 NOV 2010, DOI: 10.1002/pbc.22826

  13. You have full text access to this OnlineOpen article
    Sustained improvements in myocardial T2* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine

    American Journal of Hematology

    Volume 90, Issue 2, February 2015, Pages: 91–96, Dudley J. Pennell, John B. Porter, Antonio Piga, Yong-Rong Lai, Amal El-Beshlawy, Mohsen Elalfy, Akif Yesilipek, Yurdanur Kilinç, Dany Habr, Khaled M. Musallam, Junwu Shen, Yesim Aydinok and on behalf of the CORDELIA study investigators

    Version of Record online : 19 NOV 2014, DOI: 10.1002/ajh.23876

  14. You have full text access to this OnlineOpen article
    Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange

    European Journal of Haematology

    Volume 88, Issue 3, March 2012, Pages: 260–268, Norbert Gattermann, Andrea Jarisch, Rudolf Schlag, Klaus Blumenstengel, Mariele Goebeler, Matthias Groschek, Christoph Losem, Maria Procaccianti, Alexia Junkes, Oliver Leismann and Ulrich Germing

    Version of Record online : 24 NOV 2011, DOI: 10.1111/j.1600-0609.2011.01726.x

  15. You have full text access to this OnlineOpen article
    Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia

    British Journal of Haematology

    Volume 168, Issue 2, January 2015, Pages: 284–290, Ali T. Taher, John B. Porter, Vip Viprakasit, Antonis Kattamis, Suporn Chuncharunee, Pranee Sutcharitchan, Noppadol Siritanaratkul, Raffaella Origa, Zeynep Karakas, Dany Habr, Zewen Zhu and Maria Domenica Cappellini

    Version of Record online : 12 SEP 2014, DOI: 10.1111/bjh.13119

  16. Efficacy of deferasirox in children with β-thalassemia: Single-center 3 year experience

    Pediatrics International

    Volume 56, Issue 4, August 2014, Pages: 530–533, Ali Aycicek, Ahmet Koc and Mahmut Abuhandan

    Version of Record online : 30 MAY 2014, DOI: 10.1111/ped.12323

  17. Effect of Food, Type of Food, and Time of Food Intake on Deferasirox Bioavailability: Recommendations for an Optimal Deferasirox Administration Regimen

    The Journal of Clinical Pharmacology

    Volume 48, Issue 4, April 2008, Pages: 428–435, Dr Renzo Galanello, Dr Antonio Piga, Dr Maria Domenica Cappellini, Dr Gian Luca Forni, Dr Antonella Zappu, Dr Raffaella Origa, Dr Catherine Dutreix, Ms Rossella Belleli, Dr John M. Ford, Dr Gilles-Jacques Rivière, Dr Sébastien Balez, Dr Daniele Alberti and Dr Romain Séchaud

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270007313327

  18. You have free access to this content
    A case of hypophosphatemic osteomalacia secondary to deferasirox therapy

    Journal of Bone and Mineral Research

    Volume 27, Issue 1, January 2012, Pages: 219–222, Frances Milat, Phillip Wong, Peter J Fuller, Lillian Johnstone, Peter G Kerr, James CG Doery, Boyd J Strauss and Donald K Bowden

    Version of Record online : 22 DEC 2011, DOI: 10.1002/jbmr.522

  19. Investigation of the Pharmacokinetic Interactions of Deferasirox, a Once-Daily Oral Iron Chelator, With Midazolam, Rifampin, and Repaglinide in Healthy Volunteers

    The Journal of Clinical Pharmacology

    Volume 50, Issue 2, February 2010, Pages: 205–213, Dr Andrej Skerjanec, Dr Jixian Wang, Dr Kelly Maren and Dr Lisa Rojkjaer

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270009340418

  20. You have full text access to this OnlineOpen article
    Importance of optimal dosing ≥30 mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia

    European Journal of Haematology

    Volume 87, Issue 4, October 2011, Pages: 355–365, Ali Taher, Mohsen S. Elalfy, Kusai Al Zir, Shahina Daar, Abdullah Al Jefri, Dany Habr, Ulrike Kriemler-Krahn, Ali El-Ali, Bernard Roubert and Amal El-Beshlawy

    Version of Record online : 31 JUL 2011, DOI: 10.1111/j.1600-0609.2011.01662.x